Paper · 42883992
From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates.
Kim J and 1 other. Int J Mol Sci, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates. Papers, record 42883992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42883992
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates.
- Journal
- Int J Mol Sci
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-20
Source PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Bispecific | Major topic |
| Immunoconjugates | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Animals | |
| Translational Research, Biomedical |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| RS-2025-25441317 | Soongsil University | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38,820,153 | Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. | Sci Adv | 2024 | https://conductscience.org/library/papers/38820153 | PubMed |
| 2 | 42,497,381 | Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/42497381 | PubMed |
| 3 | 41,656,479 | Bispecific antibody-drug conjugates: a modular blueprint for next-generation cancer therapeutics. | Arch Pharm Res | 2026 | https://conductscience.org/library/papers/41656479 | PubMed |
| 4 | 42,142,622 | Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors. | Ann Oncol | 2026 | https://conductscience.org/library/papers/42142622 | PubMed |
| 5 | 38,799,638 | Bispecific antibody drug conjugates: Making 1+1>2. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38799638 | PubMed |
| 6 | 32,542,108 | Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies. | Comput Struct Biotechnol J | 2020 | https://conductscience.org/library/papers/32542108 | PubMed |
| 7 | 25,724,883 | Antibody Drug Conjugates: Preclinical Considerations. | AAPS J | 2015 | https://conductscience.org/library/papers/25724883 | PubMed |
| 8 | 39,111,317 | Therapeutic potential of cis-targeting bispecific antibodies. | Cell Chem Biol | 2024 | https://conductscience.org/library/papers/39111317 | PubMed |
| 9 | 32,355,769 | Tissue cross-reactivity studies of CPGJ701 in humans, cynomolgus monkeys and Sprague-Dawley rats and correlation analysis with in vivo toxicity. | Ann Transl Med | 2020 | https://conductscience.org/library/papers/32355769 | PubMed |
| 10 | 33,856,579 | Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor. | AAPS J | 2021 | https://conductscience.org/library/papers/33856579 | PubMed |
1 to 10 of 46
See all 46 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42883992
GET https://conductscience.org/api/papers/v1/42883992/references?page=2